

2025 Formulary Changes



Contact Customer Solutions at the number on your member ID card for more information.

These changes will be effective 4/1/25 for Commercial and Exchange plans.

Medication	Change
BRAND Sprycel	Removing BRAND from formulary since the generic for this drug, dasatinib, is covered
BRAND Stelara products	Removing BRAND Stelara products from formulary because ustekinumab biosimilars are available. Covered biosimilars include select NDCs of the following: Wezlana, Otulfi, Selarsdi, Yesintek, Steqeyma and Pyszchiva
diclofenac 25mg immediate release products	Removing from formulary due to the availability of delayed release formulations and immediate release formulations in other strengths
Enjaymo, Thiola, Xermelo	These policies will have negative changes effective 4/5/25. Please visit this link to review the new versions with upcoming changes.